Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Mouse Monoclonal [clone 2C2] (IgG1) to Human KRT5 / CK5 / Cytokeratin 5
IHC, IHC - Paraffin, Immunofluorescence, Western blot, Flow Cytometry, ELISA
Rabbit Polyclonal to Human KRT5 / CK5 / Cytokeratin 5
IHC, IHC - Paraffin
Human KRT5 / CK5 / Cytokeratin 5
Human (tested or 100% immunogen sequence identity)
IHC - Paraffin (1:100) & (10 µg/ml)
Specificity and Use
Synthetic peptide corresponding to C-terminal of human keratin 5.
Immunohistochemistry: LS-B3359 was validated for use in immunohistochemistry on a panel of 21 formalin-fixed, paraffin-embedded (FFPE) human tissues after heat induced antigen retrieval in pH 6.0 citrate buffer. After incubation with the primary antibody, slides were incubated with biotinylated secondary antibody, followed by alkaline phosphatase-streptavidin and chromogen. The stained slides were evaluated by a pathologist to confirm staining specificity. The optimal working concentration for LS-B3359 was determined to be 10 ug/ml.
10mM PBS/1% BSA buffer pH 7.4 with 0.1% sodium azide.
The protein encoded by this gene is a member of the keratin gene family. The type II cytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed during differentiation of simple and stratified epithelial tissues. This type II cytokeratin is specifically expressed in the basal layer of the epidermis with family member KRT14. Mutations in these genes have been associated with a complex of diseases termed epidermolysis bullosa simplex.